Abstracts tagged "Vasculitis"

Abstract Number: 1556 • ACR Convergence 2023
Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome
Sinem Nihal Esatoglu¹, Sabriye Guner¹, Sevim Guler², Gulen Hatemi¹, Nuray Kepil³, Yusuf Ziya Erzin⁴, Aykut Ferhat Celik⁴ and Ibrahim Hatemi⁴, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Pathology, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Gastrointestinal involvement of Behçet's syndrome (GIBS) may require surgery in up to one third of the patients. We aimed to investigate the clinical characteristics,…
Abstract Number: 1882 • ACR Convergence 2023
Imaging in Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Literature Review Informing the 2023 Update of the EULAR Recommendations
Philipp Bosch¹, Milena Bond², Christian Dejaco³, Cristina Ponte⁴, Sarah Mackie⁵, Louise Falzon⁶, Wolfgang Schmidt⁷ and Sofia Ramiro⁸, ¹Medical University of Graz, Graz, Austria, ²Azienda sanitaria dell'Alto Adige, Merano, Italy, ³Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Sheffield, Sheffield, United Kingdom, ⁷Immanuel Krankenhaus Berlin, Berlin, Germany, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Since the development of the EULAR recommendations for the use of imaging in large vessel vasculitis (LVV) in 2017, new data has emerged in…
Abstract Number: 2400 • ACR Convergence 2023
Applanation Tonometry of the Temporal Arteries in Participants with Suspected Giant Cell Arteritis: A Proof of Concept
Jean-Paul Makhzoum¹, Stephanie Ducharme-Benard², Samer Hussein², Rosalie-Selene Meunier², Carolyn Ross³, Alik Chamlian⁴, Jonathan Ducharme⁵, Leia Chamlian⁴, Alae Dhahbi⁴, Christian Pagnoux⁶ and Remi Goupil⁷, ¹Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Canadian Network for Research on Vasculitides, Montreal, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁴Laval University, Montreal, QC, Canada, ⁵University of Sherbrooke, Montreal, QC, Canada, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada
Background/Purpose: Applanation tonometry (ATn) is a non-invasive, point-of-care tool used to capture arterial pressure waveforms. It can measure arterial pulse wave velocity (PWV), a marker…
Abstract Number: 2423 • ACR Convergence 2023
Concordance Between the 1990 ACR Classification Criteria and the New 2022 ACR/EULAR 2022 Criteria in Giant Cell Arteritis
Julio Sanchez Martin¹, Julia Medina Valle¹, Javier Loricera¹, Maria Fe Garcia Reija¹ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Classification criteria for vasculitis, including giant cell arteritis (GCA) are under constant revision. In 2022, the American College of Rheumatology (ACR)/European League Against Rheumatism…
Abstract Number: 0675 • ACR Convergence 2023
Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond
allyson egan¹, Pasupathy Sivasothy² and David Jayne³, ¹Trinity Health Kidney Centre, Tallaght University Hospital, Ireland, Dublin, Ireland, ²Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ³University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…
Abstract Number: 0705 • ACR Convergence 2023
Sleep Disturbances in Patients with Vasculitis: Results of the Vasculitis Patient-Powered Research Network Sleep Study (SleepVasc)
Misa Tanaka¹, Saverio Stranges¹, Kathy Speechley¹, Osvaldo Espin Garcia¹, Molly Mason², Renee Borchin³, Cristina Burroughs³, Christine Yeung⁴, Indira Gurubhagavatula⁴, Christian Pagnoux⁵, Peter Merkel⁴ and Lillian Barra¹, ¹Western University, London, ON, Canada, ²Vasculitis Patient Powered Research Network, Philadelphia, PA, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Sleep deprivation and sleep disorders can impair health-related quality of life and increase the risk of chronic diseases, such as cardiovascular disease, and mental…
Abstract Number: 1061 • ACR Convergence 2023
Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology
Chani-mi Lee¹, Margaret Wang², Aarthi Rajkumar¹, Cassandra Calabrese³ and Leonard Calabrese³, ¹University Hospital, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Vasculitis as an immune-related adverse event (irAE) from checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known…
Abstract Number: 1558 • ACR Convergence 2023
Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement
Didar Ucar¹, Basak Ecem Bircan², Nigar Rustamli², Bilge Batu Oto¹, Vedat Hamuryudan³, Sinem Nihal Esatoglu³ and Gulen Hatemi³, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: A considerable number of patients with Behçet's syndrome (BS) have vitreous cells (VC) on slit lamp examination at the time of diagnosis. However, the…
Abstract Number: 1889 • ACR Convergence 2023
Utility of a Diagnostic Algorithm in the Assessment of Large Vessel Vasculitis
HUGO AVALOS BOGADO¹, GUSTAVO AÑEZ STURCHIO², Ernesto Trallero-Araguas³, Esther Espartal López⁴, sebastián Sandoval Moreno¹, daniela Ulloa Navas⁵ and Juan José De Agustín De Oro², ¹Rheumatology Department Vall d'Hebrón University Hospital, Barcelona, Spain, ²Vall d'Hebron University Hospital, Barcelona, Spain, ³Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁴Vall Hebron University Hospital, Rheumatology Department, Barcelona, Spain, ⁵Rheumatology Department, Vall Hebron University Hospital, Barcelona, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most prevalent type of primary systemic vasculitis among individuals aged 50 and above. Imaging techniques such as ultrasound…
Abstract Number: 2401 • ACR Convergence 2023
A Study Defining the Optimal Sonographic Parameters for Intima-Media Thickness in Diagnosing Giant Cell Arteritis
Colm Kirby¹, Sharon Cowley², Rachael Flood¹, Ronan Mullan¹, Grainne Murphy³ and David Kane⁴, ¹Tallaght University Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Ireland, ³Cork University Hospital, Cork, Ireland, ⁴Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: In recent years, Temporal Artery US (TAUS) incorporating Axillary Artery US (AAUS) has become a reliable alternative to biopsy for diagnosing GCA but studies…
Abstract Number: 2425 • ACR Convergence 2023
Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data
Amadeia Rector¹, Julia Simard², Gary Shaw³ and Audra Horomanski⁴, ¹Stanford University, San Francisco, CA, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Stanford University, Stanford, CA, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Systemic vasculitides are rare, heterogeneous, inflammatory disorders associated with high morbidity and mortality. Recent management and therapeutic advances have improved life expectancy and reproductive…
Abstract Number: 0681 • ACR Convergence 2023
Real-World Outcomes for Remission Induction in Working-Age Adults with Severe Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis
Itay Marmor¹, Katelin Nickel², Matthew Keller², Guy Hazan³, Kevin Baszis⁴, Anthony French⁵ and Mary Hartman², ¹Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ²Washington University in St. Louis, St. Louis, MO, ³Soroka University Medical Center, Beer Sheva, Israel, ⁴Washington Univ in St. Louis School of Medicine, St. Louis, MO, ⁵Washington University School of Medicine, St. Louis, MO
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), often manifests with life-threatening complications. Cyclophosphamide (CYC) and rituximab…
Abstract Number: 0706 • ACR Convergence 2023
Aortitis and Periaortitis Spectrum in 135 Patients from a Single Referral Centre
Fernando López¹, Javier Loricera², Carmen Secada³, Lucía García-Alcalde⁴, María Núñez-Savar⁴, Ander Ucelay-Aristi⁴ and Ricardo Blanco⁵, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ⁴Department of Cardiovascular Surgery, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Aortitis is the inflammation of the aortic wall, and can be idiopathic or associated with a cluster of infectious and non-infectious diseases (1-3). Periaortitis,…
Abstract Number: 1152 • ACR Convergence 2023
Relation Between Positive MPO-ANCA Antibodies And: Associated Diseases, Anca-associated Vasculitis Specificty, Severity and Prognosis. Study from a Single University Hospital
Fabricio Benavides¹, Monica Renuncio-García¹, Salma Al Fazazi², clara escagedo Cagigas¹, maria rodriguez Vidriales¹, Vanesa Calvo Río³, Juan Irure-Ventura¹, luis martin penagos⁴, Marcos Lopez-Hoyos⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Puerta Del Mar, Cádiz, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, ⁵Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of pathologies characterized by necrotizing inflammation that mainly affects small and medium-sized vessels. Serum anti-neutrophil cytoplasmic antibodies (ANCA),…
Abstract Number: 1559 • ACR Convergence 2023
Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease
Nuria Barroso-Garcia¹, Jose Luis Martin-Varillas², Lara Sanchez-Bilbao³, Ivan Ferraz Amaro⁴, Vanesa Calvo Río⁵, Alfredo Adán⁶, Inés Hernanz-Rodriguez⁷, Emma Beltran-Catalan⁸, David Diaz-Valle⁹, Marisa Hernandez-Garfella¹⁰, Lucia Martinez-Costa¹¹, Manuel Diaz-Llopis¹², Jose M Herreras¹³, Olga Maiz-Alonso¹⁴, Ignacio Torre-Salaberri¹⁵, Antonio Atanes Sandoval¹⁶, Santos Insua-Vilariño¹⁷, Raquel Almodovar¹⁸, Patricia Fanlo-Mateo¹⁹, Juan Ramon De Dios²⁰, Angel Garcia-Aparicio²¹, Sergio rodriguez-Montero²², Vega Jovani²³, Patricia Moya²⁴, Eva Peña Sainz-Pardo²⁵, Jose Luis Hernandez²⁶ and Ricardo Blanco²⁷, ¹Hospital Universitario Puerta del Mar, Cadiz, Spain, ²Hospital de Laredo, Laredo, Spain, ³Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Valdecilla Hospital, Santander, Spain, ⁶Oftalmology, Hospital Clinic de Barcelona, Barcelona, Spain, ⁷Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain, ⁸HOSPITAL DEL MAR, Barcelona, Spain, ⁹Hospital Clinico San Carlos, Madrid, Spain, ¹⁰Ophthalmology, Hospital Universitario General Valencia, Valencia, Spain, ¹¹Ophthalmology, Hospital Universitario Doctor Peset, Valencia, Spain, ¹²Ophthalmology, Hospital Universitario La Fe, Valencia, Spain, ¹³Ophthalmology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, ¹⁴University Hospital Donostia, San Sebastian, Spain, ¹⁵Hospital Universitario de Basurto, Bilbao, Spain, ¹⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, ¹⁷Rheumatology, Hospital Universitario de Santiago de Compostela, Santiago Compostela, Spain, ¹⁸Alcorcón Foundation University Hospital, Madrid, Spain, ¹⁹Internal Medicine, Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, ²⁰Osakidetza, Vitoria, Spain, ²¹Hospital Universitario de Toledo, Toledo, Spain, ²²Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, ²³Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, ²⁴Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ²⁵Pediatric, Hospital 12 de Octubre, Madrid, Spain, ²⁶Rheumatology, Ophthalmology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Cystoid macular edema (CME) is the leading cause of blindness in non-infectious uveitis. One of the most frequently associated conditions is Behçet's disease (BD)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].